Research Grade Lintuzumab,100ug,HB185026-100ug,Abinscience

Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

Host species	Humanized
Isotype	IgG1-kappa
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names	225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Note	For research use only. Not suitable for clinical or therapeutic use.